Indivior Pharmaceuticals, Inc. (INDV): debt financing — Indivior issues $500M 0.625% convertible notes due 2031; repays existing debt

Indivior Pharmaceuticals, Inc.

$500M principal of 0.625% Convertible Senior Notes due March 15, 2031 issued; initial purchasers' option fully exercised for additional $50M.
Initial conversion price of ~$41.66 per share (35% premium over March 12 close); max ~16.2M shares issuable upon conversion.
Proceeds used to prepay all outstanding principal, interest, and fees under November 2024 Note Purchase Agreement; that agreement terminated.
Notes redeemable at Indivior's option after March 20, 2029 if stock exceeds 130% of conversion price for 20 of 30 trading days.
Notes are senior unsecured, structurally subordinated to subsidiary liabilities; interest payable semi-annually on March 15 and September 15.

item 1.01 item 1.02 item 2.03 item 3.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Indivior Pharmaceuticals, Inc. incurred convertible notes of $500,000,000 principal amount with U.S. Bank Trust Company, National Association at 0.625% per annum maturing March 15, 2031.

Instrument: convertible notes
Principal: $500,000,000 principal amount
Counterparty: U.S. Bank Trust Company, National Association
Rate: 0.625% per annum
Maturity: March 15, 2031
Event: incurrence

Exact text from the filing

On March 17, 2026, Indivior Pharmaceuticals, Inc. (the “ Company ”) issued $500,000,000 principal amount of its 0.625% Convertible Senior Notes due 2031 (the “ Notes ”; the “ Convertible Notes Offering ”).

View on SEC.gov

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Indivior Pharmaceuticals, Inc. issued convertible note to initial purchasers for $500,000,000 principal amount.

Security: convertible note
Purchaser: initial purchasers
Consideration: $500,000,000 principal amount

Exact text from the filing

Section 13(a) of the Exchange Act. ☐ Item 1.01. Entry Into a Material Definitive Agreement. Indenture On March 17, 2026, Indivior Pharmaceuticals, Inc. (the “ Company ”) issued $500,000,000 principal amount of its 0.625% Convertible Senior Notes due 2031 (the “ Notes ”; the “ Convertible Notes Offering ”). The Notes were issued pursuant to, and are governed by, an

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Indivior Pharmaceuticals, Inc. entered into Indenture with U.S. Bank Trust Company, National Association valued at $500,000,000 principal amount (effective 2026-03-17).

Action: entry
Agreement: notes offering
Counterparty: U.S. Bank Trust Company, National Association
Value: $500,000,000 principal amount
Effective: 2026-03-17

Exact text from the filing

On March 17, 2026, Indivior Pharmaceuticals, Inc. (the “ Company ”) issued $500,000,000 principal amount of its 0.625% Convertible Senior Notes due 2031

View on SEC.gov

102 debt financings filed in the last 30 days. Browse all debt financings →

Indivior Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001625297-26-000015

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.